End Tidal Carbon Monoxide, End Tidal Carbon Monoxide Excretion as a Diagnostic Tool for Hemolysis in the Newborn, Neonatal Jaundice
Conditions
Keywords
Neonatal Hemolysis, Neonatal Jaundice, ETCO, End Tidal Carbon Monoxide
Brief summary
The purpose of this study is to evaluate if adding a noninvasive testing of End Tidal Carbon Monoxide with a FDA approved device will help improve management of jaundice in the Neonates by reducing the number of lab draws, Coombs tests and optimizing the number of phototherapy hours in Neonates who need it. Eligible subjects will be Term and healthy late preterm newborns born at Cedars-Sinai Medical Center and admitted to well baby nursery from November 2020 onwards. The primary procedure of measuring an End-Tidal Carbon monoxide in a Newborn is going to be with a soft cannula applied to the Newborn's nose for a few minutes. The whole procedure will take about 15+ 5 minutes. Subject participation will last approximately 6 months and all subjects will be followed up with one phone call at about 2-4 weeks of age. Adding ETCO testing to current standard of care might reduce the number of lab draws in a newborn and potentially reduce costs by optimizing the number of phototherapy hours in a Newborn who needs it. Cedars- Sinai Medical Center will not be billing the patients for the End-Tidal Carbon Monoxide measurement for this study.
Detailed description
The purpose the research is: * Whether near simultaneous measurements of Total Serum bilirubin (Tsb) & End-Tidal Carbon Monoxide (End-Tidal Carbon monoxide as a function of bilirubin) will help identify hyperbilirubinemia accurately and easily This has been shown in a single center study. * Whether near simultaneous measurement of Total serum bilirubin & End Tidal Carbon Monoxide is more accurate and less costly in overall management of Neonatal Hyperbilirubinemia Eligible infants would be male or female with GA \> 35 weeks and BW \> 2000, post natal age 6 hours to \< 6 days of age and meets any one of the following criteria * Due for an early discharge * Has a Transcutaneous bilirubin or a Total serum bilirubin on or \> the 75th % of Bhutani hyperbilirubinemia nomogram * Has 2 or more risk factors for neonatal jaundice as specified in the protocol * The study includes 388 patients in each arm - \ 776 total newborn admissions * The total study duration is: 6 months Methods: a retrospective group (Standard of Care) will be compared with a prospective Group (Standard of care + End-Tidal Carbon monoxide). Informed Consent will be obtained before the subject is recruited in the prospective group. A phone call will be made to each subject in the prospective group at 2-4 weeks of age post birth hospitalization. This is a minimally risk study.
Interventions
DIAGNOSTIC_TESTEnd Tidal Carbon Monoxide Value
A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
Sponsors
Cedars-Sinai Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Retrospective review of subjects for Standard of Care for Neonatal jaundice diagnosis and management (SOC) will be compared with a prospective group of subjects with Standard of care for Neonatal jaundice for diagnosis and management + End Tidal Carbon Monoxide management (ETCO)
Eligibility
Sex/Gender
ALL
Age
35 Weeks to 44 Weeks
Healthy volunteers
Yes
Inclusion criteria
* male or female with GA \> 35 weeks and BW \> 2000, post natal age 6 hours to \< 6 days of age and meets any one of the following criteria * Due for an early discharge * Has a TcB or Tsb on or \> the 75th % of Bhutani hyperbilirubinemia nomogram * Has 2 or more risk factors for neonatal jaundice as specified in the protocol
Exclusion criteria
* babies requiring any kind of respiratory support (O2, CPAP or assisted ventilation) has severe or life threatening congenital anomalies, weighed less than 2000 gms and if their mother has a known history of smoking during 3rd trimester of pregnancy. Also in addition nasal mucosal abrasion or nasal mucosal abnormalities will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in usage of Coombs Test and other Labs Ordered for hemolysis in Neonatal Jaundice | 6 months | We expect a projected change of 10-15% in Coombs Test usage for neonatal jaundice and mean difference of 1 in other labs ordered for hemolysis in neonatal jaundice |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adding ETCO to diagnostic procedures for hemolysis in neonatal jaundice will help optimize phototherapy | 6 months | On average on readmission at Cedars- Sinai Medical Center a newborn gets 36 +/-10 hours of phototherapy and on birth admission some babies are getting 6 +/- 12 hours of phototherapy. ETCO (End tidal carbon monoxide value) used a function of Total serum bilirubin will help optimize the number of hours of phototherapy. |
| Recording of nursing time to perform the test | 6 months | The time taken by medical personnel to perform and record results will be recorded |
Contacts
Primary ContactJyotirbala N Ruparel, MD
Outcome results
None listed